One-Dose Pill Could Erase Sleeping Sickness

European drug regulators have given their approval to acoziborole, a new and simplified treatment for sleeping sickness. Developed by Sanofi, this medication requires only a one-time dose of three pills, offering a significant improvement over current complex and arduous treatment regimens. This endorsement is a crucial step towards making the drug available in Congo, the country most impacted by the disease, and potentially other African nations.

Sleeping sickness, spread by tsetse flies in sub-Saharan Africa, can cause severe neurological damage and death if untreated. Efforts to combat it have relied on controlling the fly population and difficult-to-administer medications. The new drug is seen as a potential game-changer, especially as the World Health Organization aims to halt the spread of the most common form by 2030. Sanofi has pledged to donate doses, ensuring free access for patients.

While researchers are optimistic, some caution that the parasite's ability to evade immune responses and its hidden presence still pose challenges. However, studies indicate over 95% cure rates, and the drug can treat both early and advanced stages, eliminating the need for spinal taps. If sleeping sickness is eliminated, it would be a historic achievement in global health.